Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 DiabetesRalph A. DeFronzo, Steven C. Griffen, Marcus Hompesch et al.|Diabetes Care|2013Cited by 289
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Sreeneeranj Kasichayanula, David W. Boulton, Steven C. Griffen et al.|Clinical Pharmacokinetics|2013Cited by 277
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or DigoxinSreeneeranj Kasichayanula, David W. Boulton, Ming Chang et al.|Advances in Therapy|2012Cited by 62
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese SubjectsYang Li, David W. Boulton, Haiyan Li et al.|Clinical Therapeutics|2013Cited by 43
Global characterization of megakaryocytes in bone marrow, peripheral blood, and cord blood by single-cell RNA sequencingWeilong Zhang, Hongmei Jing, Changjian Yan et al.|Cancer Gene Therapy|2022Cited by 15